TMO
Thermo Fisher Scientific Inc
NYSE: TMO · HEALTHCARE · DIAGNOSTICS & RESEARCH
$478.96
+2.72% today
Updated 2026-04-30
Market cap
$173.27B
P/E ratio
25.65
P/S ratio
3.83x
EPS (TTM)
$18.18
Dividend yield
0.37%
52W range
$384 – $643
Volume
2.0M
Thermo Fisher Scientific Inc (TMO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
15.10%
Operating margin
17.90%
ROE
13.50%
ROA
5.00%
Debt/equity
0.74x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $3.79B | $168.94M | 44.49% | 9.63% | 4.46% |
| 2007 | $9.75B | $761.10M | 39.95% | 10.94% | 7.81% |
| 2008 | $10.50B | $994.20M | 40.41% | 12.06% | 9.47% |
| 2009 | $10.11B | $850.30M | 40.26% | 11.06% | 8.41% |
| 2010 | $10.79B | $1.04B | 39.62% | 11.72% | 9.60% |
| 2011 | $11.73B | $1.33B | 41.50% | 12.63% | 11.34% |
| 2012 | $12.51B | $1.18B | 43.28% | 13.02% | 9.42% |
| 2013 | $13.09B | $1.27B | 42.98% | 13.74% | 9.73% |
| 2014 | $16.89B | $1.89B | 46.69% | 13.90% | 11.22% |
| 2015 | $16.97B | $1.98B | 46.20% | 14.70% | 11.64% |
| 2016 | $18.27B | $2.02B | 46.96% | 15.64% | 11.06% |
| 2017 | $20.92B | $2.23B | 46.27% | 15.62% | 10.64% |
| 2018 | $24.36B | $2.94B | 45.11% | 15.90% | 12.06% |
| 2019 | $25.54B | $3.70B | 44.41% | 16.67% | 14.47% |
| 2020 | $32.22B | $6.38B | 49.75% | 24.51% | 19.79% |
| 2021 | $39.21B | $7.72B | 50.07% | 26.31% | 19.70% |
| 2022 | $44.91B | $6.95B | 42.33% | 18.98% | 15.47% |
| 2023 | $42.86B | $6.00B | 40.98% | 16.00% | 13.99% |
| 2024 | $42.88B | $6.33B | 41.34% | 17.87% | 14.77% |
| 2025 | $44.56B | $6.74B | 37.66% | 18.20% | 15.12% |